指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

中性粒细胞减少患者抗菌预防共识指南

Consensus guidelines for antibacterial prophylaxis in patients with neutropenia.
指南 / 共识 · Intern Med J · 2025-01-01
一句话结论在多数情况下,抗菌预防减少感染发生率但不降低死亡率,其耐药、不良反应及微生态破坏风险超过获益。

该更新版共识指南由澳大利亚发布,评估成人和儿童接受癌症治疗相关中性粒细胞减少时抗菌预防的获益与危害。指南基于当前证据,并考虑澳大利亚和新西兰医疗环境。在多数情况下,抗菌素耐药、抗生素不良反应及微生态破坏的潜在危害超过减少感染发生率的获益,且无死亡率获益。

要点

  • 在多数情况下,抗菌预防减少感染发生率的获益不伴死亡率获益,其耐药、不良反应及微生态破坏风险超过获益。
  • 指南推荐基于当前证据对中性粒细胞减少患者抗菌预防获益与危害的评估,并考虑澳大利亚和新西兰医疗环境。
  • 自2011年澳大利亚共识指南发布以来,中性粒细胞减少患者常规使用预防性抗生素仍存争议。
  • 风险人群已变化,包括接受靶向治疗和免疫治疗等多种新癌症疗法的患者。
  • 对微生态在治疗反应和抗生素耐药模式中作用的认识已扩展,中性粒细胞减少性发热管理因脓毒症路径的常规实施而显著改善。

适用人群与场景

  • 接受与中性粒细胞减少相关的癌症治疗的成人和儿童。

研究设计与关键结果

  • 制定机构:澳大利亚共识指南更新版;方法:评估当前抗菌预防获益与危害的证据,并考虑澳大利亚和新西兰医疗环境。

证据类型、等级与局限

  • 证据类型:共识指南。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在多数情况下,抗菌预防减少感染发生率的获益不伴死亡率获益,其耐药、不良反应及微生态破坏风险超过获益。
  • 风险人群已变化,包括接受靶向治疗和免疫治疗等多种新癌症疗法的患者。
  • 中性粒细胞减少性发热管理因脓毒症路径的常规实施而显著改善。

指南或共识出处

  • 中性粒细胞减少患者抗菌预防共识指南,Intern Med J。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Since the publication of the Australian consensus guidelines in 2011, the routine use of prophylactic antibiotics in patients with neutropenia has remained controversial, because of concern that the risks of promoting antimicrobial resistance outweighed the level of evidence that their use reduced mortality. Populations at risk have changed over this period and now include a multitude of new cancer therapies, such as targeted cancer therapies and immunotherapies. Emerging understanding about the importance and role of the microbiome in defining treatment response and patterns of antibiotic resistance has also expanded. In addition, the management of neutropenic fever has improved significantly through the development and routine implementation of sepsis pathways. These updated consensus guidelines review recent evidence for the use of antibacterial prophylaxis in adults and children receiving cancer therapies associated with neutropenia. Recommendations presented in these guidelines were based on evaluating current evidence for the benefits and harms of antibacterial prophylaxis while considering the current Australian and New Zealand healthcare setting. In most circumstances, the potential harm of antibiotic resistance, adverse effects of antibiotics and disruption to the microbiome, outweighed the benefit of reducing the incidence of infection, without a benefit in mortality.

来源:Intern Med J,查看原文。版权归原作者所有。

参考来源

  1. Lindsay J, Yeoh D, Teh BW, et al. Consensus guidelines for antibacterial prophylaxis in patients with neutropenia. Intern Med J. 2025. PMID: 41521409. doi:10.1111/imj.70250

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。